CN116421688A - 一种固体饮料及其制备方法和应用 - Google Patents
一种固体饮料及其制备方法和应用 Download PDFInfo
- Publication number
- CN116421688A CN116421688A CN202310401442.6A CN202310401442A CN116421688A CN 116421688 A CN116421688 A CN 116421688A CN 202310401442 A CN202310401442 A CN 202310401442A CN 116421688 A CN116421688 A CN 116421688A
- Authority
- CN
- China
- Prior art keywords
- parts
- solid beverage
- uric acid
- group
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007787 solid Substances 0.000 title claims abstract description 70
- 235000013361 beverage Nutrition 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 43
- 201000005569 Gout Diseases 0.000 claims abstract description 39
- 206010018634 Gouty Arthritis Diseases 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 12
- 241000234435 Lilium Species 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract description 12
- 235000013372 meat Nutrition 0.000 claims abstract description 12
- 235000020234 walnut Nutrition 0.000 claims abstract description 12
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 11
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 11
- 235000009569 green tea Nutrition 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 10
- 244000197580 Poria cocos Species 0.000 claims abstract description 10
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 10
- 240000000249 Morus alba Species 0.000 claims abstract description 9
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 9
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 8
- 240000006432 Carica papaya Species 0.000 claims abstract description 4
- 244000298479 Cichorium intybus Species 0.000 claims abstract 3
- 240000007049 Juglans regia Species 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 56
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 43
- 229940116269 uric acid Drugs 0.000 abstract description 43
- 210000003734 kidney Anatomy 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 18
- 230000006378 damage Effects 0.000 abstract description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 11
- 229910052708 sodium Inorganic materials 0.000 abstract description 11
- 239000011734 sodium Substances 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 210000000845 cartilage Anatomy 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 208000006820 Arthralgia Diseases 0.000 abstract description 6
- 230000003628 erosive effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 206010003694 Atrophy Diseases 0.000 description 16
- 230000037444 atrophy Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000001434 glomerular Effects 0.000 description 15
- 210000004969 inflammatory cell Anatomy 0.000 description 15
- 230000001603 reducing effect Effects 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000000544 articulatio talocruralis Anatomy 0.000 description 14
- 230000008595 infiltration Effects 0.000 description 14
- 238000001764 infiltration Methods 0.000 description 14
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 201000001431 Hyperuricemia Diseases 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 241000758789 Juglans Species 0.000 description 9
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical group [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- 210000003423 ankle Anatomy 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 241000723343 Cichorium Species 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 241000721047 Danaus plexippus Species 0.000 description 7
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000008719 thickening Effects 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 241000219173 Carica Species 0.000 description 6
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229960004945 etoricoxib Drugs 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229960001338 colchicine Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000008721 basement membrane thickening Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000738 kidney tubule Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229940083914 URAT1 inhibitor Drugs 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 231100000853 glomerular lesion Toxicity 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供一种固体饮料及其制备方法和应用,涉及新药开发技术领域。一种固体饮料,按重量份数计,包括:薏苡仁150‑200份,菊苣50‑80份,茯苓50‑80份,百合50‑80份,葛根50‑80份,桑叶20‑40份,木瓜20‑40份,金银花20‑40份,绿茶5‑20份和核桃肉5‑20份。本发明的固体饮料具有祛湿通络的功效,在痛风缓解期靶向湿邪困滞骨节,通行骨节之痹阻,驱邪而不伤正,能够有效抑制尿酸钠盐诱导的炎症反应,减少软骨的侵蚀及破坏;有效降低尿酸及保护肾脏,对肝肾器官无损害,能有效治疗痛风性关节炎,同时安全性高,原料常见,价格低廉,可以减轻经济负担。
Description
技术领域
本发明涉及新药开发技术领域,具体而言,涉及一种固体饮料及其制备方法和应用。
背景技术
随着我国经济的发展与居民饮食结构的变化,高尿酸血症、痛风性关节炎发病率逐年上升,成为继糖尿病后第二大代谢性疾病,并与代谢综合征、冠状动脉粥样硬化性心脏病、心力衰竭的发生密切相关。高尿酸血症是痛风性关节炎前期的一个重要病理阶段,据流行病学调查显示,我国高尿酸血症患病率为13.3%,痛风患病率为1.1-3%,以中年男性发病最为多见,并逐渐出现年轻化趋势。痛风性关节炎给患者带来的不仅有关节的剧烈疼痛,而且因长期未及时、规范治疗高尿酸血症,而进展至痛风性肾病期将是一个巨大的身心和医疗负担。
正常人体内尿酸的生成与代谢处于一个平衡状态,当摄入的大量含嘌呤食物时,肝脏内黄嘌呤氧化酶迅速将黄嘌呤氧化成次黄嘌呤,加速了尿酸的生成;同时,肾脏是尿酸代谢的重要场所,当肾功能受损、尿酸转运功能下降,排泄受阻,也会出现尿酸的蓄积,导致高尿酸血症的发生。而血液尿酸浓度超过饱和度时,析出的尿酸盐晶体沉积于关节、极头、韧带处,诱发关节免疫炎症反应,为痛风性关节炎。所以,对尿酸的控制能一定程度避免痛风性关节炎的发生。
当前治疗痛风性关节炎主要目的为消炎止痛缓解症状,降低血尿酸预防和改善肾损害。现有的痛风治疗方式主要有两种:(1)抗炎止痛药:包括秋水仙碱、非甾体类止痛药和糖皮质激素。这三类药物能够缓解部分患者关节疼痛症状,但治标不治本,并不能从根本上有效治疗痛风性关节炎,而且,秋水仙碱和非甾体类止痛药存在着胃肠道等不良反应大的问题,秋水仙碱还有骨髓抑制等不良反应,其中毒量常与体内蓄积剂量相关,长期治疗效果不佳,且不能用于患有哮喘等呼吸系统疾病、急性心血管疾病、慢性肾脏病的患者;糖皮质激素主要是起到抑制炎症反应作用,但局部或全身应用激素会增加关节腔感染及骨坏死风险。(2)降尿酸药:包括XOD酶抑制剂和URAT1抑制剂。前者常用的有别嘌醇和非布司他,后者为苯溴马隆。在降尿酸治疗中,上述两种机制降酸药已被报道出严重不良反应,如别嘌醇有严重药疹出现、非布司他有心血管不良事件发生、苯溴马隆有爆发性肝炎发生。当痛风性关节炎进入缓解期后,或平素有高尿酸血症的患者,此时应予降尿酸治疗,但开始降酸治疗时,体内尿酸波动,尿酸盐溶解进入血液,可能会诱发关节发生疼痛。因此,探索与开发一种无副降酸、精准抗炎、靶向护肾的多靶点药物对治疗痛风性关节炎显得尤为迫切和重要。很多研究表明中药在治疗痛风性关节炎中,在疗效性、安全性、适用性比西药更有优势,值得进一步研究与临床推广。
中医理论认为:痛风性关节炎发病因本于湿困体内,久蕴不解,与热搏结,引动风邪,助湿热毒邪流注全身经脉骨节,故痛风性关节发病部位可见四肢关节处。缓解期多因湿邪留恋不解,盘踞经脉骨节,有毒从湿之势,因此患者可见有肢体困重,酸楚疼痛不适,此时治疗应以祛湿通络为主。
目前,市面上抗痛风药物作用靶点单一,不能同时有效覆盖痛风性关节炎各病理阶段所带来的的器官组织损害。而西药对痛风性关节炎的治疗存在胃肠道应激、骨髓抑制等不良反应,后续疾病管理中降尿酸药物也存在剥脱性皮炎、爆发性肝炎等不良反应,对疾病序贯治疗存在一定风险。同时在痛风缓解期或高尿酸血症初始降尿酸时,常需配合消炎止痛药预防尿酸波动引起的关节炎炎症反应,这种预防、联合用药常增加药物的不良反应发生。
发明内容
本发明的目的在于提供一种固体饮料,具有祛湿通络的功效,在痛风缓解期靶向湿邪困滞骨节,通行骨节之痹阻,驱邪而不伤正。
本发明的目的在于提供一种固体饮料的制备方法,将原料粉碎,加水煎煮,过滤得到煎煮液,将煎煮液浓缩干燥,制成中药制剂。
本发明的目的在于提供一种固体饮料在制备预防和/或治疗痛风性关节炎的药物中的应用。
本发明解决其技术问题是采用以下技术方案来实现的。
本发明提出一种固体饮料,按重量份数计,包括以下原料:薏苡仁150-200份,菊苣50-80份,茯苓50-80份,百合50-80份,葛根50-80份,桑叶20-40份,木瓜20-40份,金银花20-40份,绿茶5-20份和核桃肉5-20份。
本发明提出一种固体饮料的制备方法,包括以下步骤:
将原料粉碎,加水煎煮,过滤得到煎煮液,将煎煮液浓缩干燥,即得固体饮料。
本发明至少具有以下有益效果:
本发明中,方中以薏苡仁为君药,味甘、淡,性凉,走脾、胃、肺经,《神农本草》曾言:薏苡仁能“下气祛湿,解痹消痈”,具有清热祛湿之功效,能调脾胃运化,使体内津液舒布得以畅通,无湿聚之意,为方中之君;臣以味苦性凉的菊苣,配合君药加强祛湿之功,还兼有健胃消食,恢复脾胃运化功能,进一步调畅脾胃之功,菊苣具有降尿酸、抗炎、抗氧化和保护软骨作用;配合茯苓加强君药祛湿除痹通络的功用,其中茯苓能助君药引关节之湿毒下行,并解关节湿毒之侵蚀,通关节湿毒之痹阻,通利四肢;配合味甘性寒的百合,归心肺二经,具有养阴清肺、清心安神之功,为常用的药食同源中药之一,《日华子本草》指出其可“安心,定胆,益志,养五脏”,其可助君药清热防湿热互结扰动君主神明,另外可防渗利过度耗竭阴液;鉴于痛风性关节炎缓解湿困于内,易合风、热之邪,凝于肌表,故臣味甘性凉葛根,将肌表之湿毒邪气透解而祛,兼有清热之功防湿与热相搏结。佐以木瓜和胃化湿,疏通经络,引经脉湿邪从下焦而去;配合性甘寒桑叶、金银花,佐君除痛风稽留关节、血脉之热邪;其中加入药食同源的绿茶、核桃肉,其要以在能减缓君臣药性寒凉,还可清心、祛湿、补肾、通便,绿茶所含的茶多酚能抗疲劳、利尿、减脂,能治疗痛风缓解期湿毒困内所引起的“首如裹”的症状,而核桃肉的配伍在痛风缓解期,谨防久病及肾,肾气受损,配合核桃肉食疗以防治。本方一君四臣五佐助,共奏除湿化毒通络之功,适用于痛风缓解期遗留关节炎症表现患者以及长期高尿酸血症、并出现肾功能损害患者。
几者配合能够有效抑制尿酸钠盐诱导的炎症反应,减少软骨的侵蚀及破坏;有效降低尿酸及保护肾脏,对肝肾器官无损害,安全性高;同时组方原料常见,易获得,价格低廉。其能够为治疗痛风性关节炎提供新的药物治疗方案,可以减轻因疾病所带来的的经济负担。
附图说明
图1为小鼠踝关节肿胀变化示意图;
图2为小鼠踝关节HE染色示意图,蓝色箭头为炎性细胞浸润,黑色箭头为滑膜增生;
图3为小鼠踝关节番红固绿染色示意图,黑色箭头为关节面缺损、欠光滑,蓝色箭头为关节软骨细胞;
图4为小鼠踝关节1L-1β免疫组化示意图,黑色箭头为阳性表达部位;
图5为小鼠踝关节1L-6免疫组化示意图,黑色箭头为阳性表达部位;
图6为小鼠踝关节TNF-α免疫组化示意图,黑色箭头为阳性表达部位;
图7为小鼠踝关节1L-4免疫组化示意图,黑色箭头为阳性表达部位;
图8为小鼠踝关节1L-10免疫组化示意图,黑色箭头为阳性表达部位;
图9为小鼠踝关节Arg免疫组化示意图,黑色箭头为阳性表达部位;
图10为小鼠踝关节TGF-β1免疫组化示意图,黑色箭头为阳性表达部位;
图11为药物干预后小鼠肾功能、肝XOD酶变化趋势以及ABCG2荧光强度示意图,A为血尿酸变化趋势图,B为血肌酐变化趋势图,C为终末尿素氮变化趋势图,D为肝脏XOD酶变化趋势图,E为ABCG2荧光强度变化图;
图12为小鼠肾脏ABCG2蛋白免疫荧光图;
图13为小鼠肾脏HE染色示意图,黑色箭头为炎症细胞浸润,红色箭头为肾小球萎缩,黄色箭头为肾小球扩张,蓝色箭头为刷状缘消失;
图14为小鼠肾脏Masson染色示意图,黑色箭头为肾小球萎缩,黄色箭头为胶原纤维沉积,绿色箭头为基底膜增厚;
图15为小鼠肾脏PAS染色示意图,黑色箭头为肾小球萎缩,红色箭头为炎症细胞浸润,绿色箭头为系膜增厚;
图16为小鼠肝脏HE染色示意图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本发明。
一种固体饮料,按重量份数计,包括以下原料:薏苡仁150-200份,菊苣50-80份,茯苓50-80份,百合50-80份,葛根50-80份,桑叶20-40份,木瓜20-40份,金银花20-40份,绿茶5-20份和核桃肉5-20份。
薏苡仁利水渗湿,健脾止泻,除弊排脓,解毒散结。菊苣清肝利胆,健胃消食,利尿消肿。茯苓滋阴除湿,清热解毒,强化筋骨。百合解毒、理脾健胃,利湿消积,宁心安神,促进血液循环。葛根透解肌表风热,解肌退热而发表,透发疹斑,又鼓舞脾胃清阳上升而生津止渴、升阳止泻。桑叶疏散风热,清肺润燥,清肝明目。木瓜舒筋活络,和胃化湿。金银花清热解毒,疏散风热。绿茶降低血糖血脂胆固醇,延缓衰老,抗氧化,是一种天然的自由基清除剂。核桃肉补肾温肺,缓解疲劳,润肠润肌肤,乌须发。
详细地,固体饮料按重量份数计,包括以下原料:薏苡仁180份,菊苣60份,茯苓60份,百合60份,葛根60份,桑叶30份,木瓜30份,金银花30份,绿茶10份和核桃肉10份。
一种固体饮料的制备方法,包括以下步骤:
将原料粉碎成100-200目的粉末,加水煎煮,煎煮温度为70-100℃,煎煮时间为30-60min,过滤得到煎煮液,将煎煮液浓缩干燥,即得固体饮料。
上述固体饮料在制备预防和/或治疗痛风性关节炎的药物中的应用,能够为治疗痛风性关节炎提供新的药物治疗方案,同时组方原料常见,易获得,价格低廉,能减轻因疾病所带来的的经济负担。
其中,预防和/或治疗痛风性关节炎的药物还包括药学上可接受的载体或辅料。辅料可以是填充剂、粘合剂、矫味剂、着色剂或增稠剂等。
详细地,药物为冲剂、散剂、片剂、丸剂、口服液、胶囊或软胶囊。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
一种固体饮料的制备方法,包括以下步骤:
原料:薏苡仁180g,菊苣60g,茯苓60g,百合60g,葛根60g,桑叶30g,木瓜30g,金银花30g,绿茶10g和核桃肉10g;
将原料粉碎成150目的粉末,加水煎煮,煎煮温度为90℃,煎煮时间为40min,过滤得到煎煮液,将煎煮液浓缩干燥,加入药学上可接受的辅料制成颗粒剂。
实施例2
一种固体饮料的制备方法,包括以下步骤:
原料:薏苡仁150g,菊苣50g,茯苓50g,百合50g,葛根50g,桑叶20g,木瓜20g,金银花20g,绿茶5g和核桃肉5g;
将原料粉碎成100目的粉末,加水煎煮,煎煮温度为70℃,煎煮时间为30min,过滤得到煎煮液,将煎煮液浓缩干燥,加入药学上可接受的辅料制成片剂。
试验结果
实验方案:
①C57BL/6]小鼠(20-22g)随机分为5组:A空白组、B模型组、C别嘌醇组、D依托考昔组、E固体饮料组(n=10)。
②将1mg氧嗪酸钾和10g酵母膏溶解在20ml羧甲基纤维素中,用超声清洗机充分超声震碎60min,形成混悬液。按小鼠体重0.1ml/10g进行灌胃,每日1次,造模时间为35天,建立高尿酸血症小鼠模型,每7天眼眶采血监测血尿酸水平;空白组用等体积羧甲基纤维素进行灌胃(灌胃体积同0.1ml/10g)。
③第29天是将1g尿酸钠盐溶于20ml无菌羧甲基纤维素中,用超声清洗机充分超声震碎60min,形成尿酸钠盐溶液,在异氟烷吸入麻醉下,消毒后往小鼠双踝关节注射80ul尿酸钠盐溶液;用游标卡尺测量各组小鼠注射前后、及注射后12h、24h、48h、72h踝关节直径记录肿胀程度。
④第29天在注射后尿酸钠2h后进行药物灌胃治疗(A、B组灌服羧甲基纤维素,C组灌服别嘌醇,D组灌服依托考昔,E组灌服实施例1的固体饮料),灌胃体积均为0.1ml/10g,药物灌胃治疗时间均为7天。
⑤第35天灌胃2h后处死小鼠,每组分别采集小鼠血液、踝关节、肝肾标本,血液离心得到血清进行血尿酸、血肌酐、尿素氮测定,踝关节进行苏木精-伊红(HE)染色、番红固绿染色、免疫组化(IL-1B、IL-6、TNF-a、IL-4、IL-10、Arg、TGF-β1)测定;肝脏研磨测量XOD酶活性、HE染色;肾脏进行免疫荧光(ABCG2)测定、HE、Masson、PAS染色。
小鼠踝关节注射方法:小鼠麻醉后常规伏消毒,在小鼠双侧踝关节外侧后方,将注射针针口斜面与胫骨成45°夹角插入踝关节腔,将配制好的浓度为50mg/ml的无菌尿酸钠盐溶液80ul注入关节腔内,空白组用相同剂量的无菌羧甲基纤维素溶液同法注射,以关节囊对侧鼓胀为注入标准,从而制备急性痛风性关节炎模型。
其中,取实施例1的颗粒剂10g,按照体表面积计算法,20g小鼠与人体表面积之比是0.0026,成人体质量按60kg计算,即小鼠灌服固体饮料的等效量为1.517g/kg,相应小鼠别嘌醇等效用量为15.167mg/kg,依托考昔等效用量为18.2mg/kg。
(1)抗炎作用上:①如图1所示,用药治疗前3天踝关节肿胀程度相比中,与模型组相比,依托考昔组能显著减低关节肿胀(P<0.001),并且固体饮料组能一定程度减轻踝关节肿胀(P=0.007);②如图2所示,踝关节HE染色中,与空白组相比,模型组小鼠踝关节滑膜增生明显,滑膜排列紊乱,并有炎性细胞浸润;与模型组相比,别嘌醇组踝关节滑膜增生现象未改善,可见炎症细胞浸润;而依托考昔组能显著减轻滑膜增生,减少炎症细胞浸润;固体饮料组经治疗,能有效减轻关节滑膜增生,并减轻炎症细胞浸润;③如图3所示,番红固绿染色中,模型组关节软骨排列紊乱,软骨面轻微破坏,可见失染现象,经固体饮料干预后,上述病理现象得到改善;④如图4-6所示,踝关节IHC中,经造模后,模型组中的IL-1β、IL-6、TNF-a炎症因子阳性表达明显上升,经固体饮料治疗后,上述炎症因子得到有效抑制及减少;⑤如图7-10所示,在抗炎因子中L-4、L-10、Arg、TGF-β1得到上升,能够有效抗炎。
(2)降尿酸作用上:①如图11A所示,用药治疗1周后,空白组血尿酸维持在基线水平,与前4周相比无明显变化;模型组血尿酸比第4周时继续升高;与模型组相比,别嘌醇组能明显有效降低血尿酸水平(P<0.001);固体饮料组经治疗后,有明显的降尿酸疗效(P<0.001);而依托考昔组无降尿酸作用(P>0.05)。②如图11E和图12所示,尿酸转运体蛋白ABCG2免疫荧光中:空白组、模型组、依托考昔组、别嘌醇组表达无增加;固体饮料组能上调ABCG2蛋白的表达(P=0.047)。③如图11D所示,肝脏黄嘌呤氧化酶中:与空白组相比,模型组表达可见明显上升(P<0.001);与模型组相比,别嘌醇组可见显著抑制黄嘌呤氧化酶(P<0.001),而且固体饮料组用药后能明显有效抑制其表达(P<0.001),但依托考昔组不能有效抑制黄嘌呤氧化酶表达(P=0.918)。因此表明,固体饮料能有效降低血尿酸水平,其潜在机制可能为促进肾脏ABCG2蛋白表达,增加尿酸排泄,并且抑制肝脏XOD酶的表达,减少尿酸生成,有双靶点降尿酸作用。
(3)护肾上:①如图11B所示,用药治疗1周后,空白组血肌酐维持在基线水平,与前4周相比无明显变化(P>0.05),与空白组对比,模型组血肌酐有明显上升(P<0.001),别嘌醇组用药后能明显有效降低血肌酐水平(P<0.001);固体饮料组对血肌酐水平也起到一定降低作用(P<0.001),但依托考昔组用药后无降血肌酐作用(P=0.179)。②如图11C所示,用药治疗1周后,与空白组相比,模型组尿素氮明显升高(P<0.001);与模型组相比,别嘌醇组能有效降低尿素氮水平(P<0.001),且固体饮料组经用药治疗后对尿素氮水平有降低作用(P=0.007);而依托考昔组相比模型组中,尿素氮水平无变化,无降尿素氮作用(P=0.427)。③如图13所示,肾脏HE染色中,空白组中肾脏结构清晰,肾小管未见扩张,肾小管间质未见炎症细胞浸润,肾小球饱满,无萎缩;而模型组肾脏小管可见扩张、且刷状缘消失;肾小管间质可见有炎症细胞浸润,肾小球可见明显萎缩,并呈分页状;经治疗后,别嘌醇组中肾小管扩张明显改善、刷状缘可见;肾小管间质炎症细胞浸润减轻,同时肾小球萎缩成度明显改善,未见肾小管上皮细胞坏死;固体饮料组肾小管扩张、肾小球萎缩均有明显改善,肾小管刷状缘可见,肾小管间质炎症细胞浸润可见一定程度的改善;而依托考昔组中肾小管有所扩张,肾小管间质炎症细胞浸润和肾小球萎缩未见改善。④如图14所示,肾脏Masson染色中,空白组中肾组织基本正常,无明显胶原纤维蓝色染色,肾小球无萎缩、基底膜无增厚;模型组可见肾间质和肾小球的胶原纤维蓝色染色,蛋白沉积显著增加,成纤维化改变,其中肾小球明显萎缩,基底膜明显增厚;经治疗后,与模型组相比,别嘌醇组中肾间质和肾小球的胶原纤维蓝色染色明显减少,蛋白沉积明显减少,纤维化改变得到有效改善,肾小球萎缩明显改善,基底膜仍有增厚,但不及模型组;并且,固体饮料组肾间质和肾小球胶原纤维染色减少,蛋白沉积减少,成纤维化程度减轻,肾小球萎缩和基底膜增厚有所改善;而依托考昔组中肾间质和肾小球的胶原纤维蓝色染色未见明显改变,蛋白沉积无改善,成纤维化改变,肾小球萎缩和基底膜增厚无改善,与模型组相仿。⑤如图15所示,肾脏PAS染色中,正常组中肾组织基本正常,肾小球无萎缩、系膜无增厚;模型组中可见肾小球明显萎缩,肾小球系膜明显增厚;经用药治疗后,别嘌醇组肾小球萎缩、系膜增厚有所改善;并且固体饮料组肾小球萎缩和系膜增厚也相应得到改善;但依托考昔组肾小球萎缩和系膜增厚则未见改善。
结果表明,固体饮料能通过降低尿酸水平,一定程度上降低血肌酐、尿素氮水平,从而减轻尿酸盐对肾脏的损害,起到保护肾脏的作用。
(4)药物安全性上:如图16所示,固体饮料未对肝肾造成损害(,并且百苓薏风固体饮料能治疗高尿酸引起的肾病病变。
根据以上结果可知,(1)固体饮料能有效抗炎、保护软骨:①免疫组化中发现固体饮料组可减低AGA小鼠的踝关节滑膜、软骨的IL-1β、IL-6、TNF-a炎症因子的表达,并且促进了IL-4、IL-10、TGF-β1、Arg等抗炎因子的表达,从而减轻了踝关节的炎症肿胀情况;②踝关节HE中发现固体饮料可减轻尿酸钠诱导的滑膜增生以及炎症细胞浸润;③番红固绿中发现,固体饮料能一定程度上改善尿酸钠晶体造成的软骨侵蚀与破坏。
(2)固体饮料能有效抑制尿酸生成、重吸收,并促进尿酸排泄,从而降低尿酸水平:①血尿酸指标中发现固体饮料组能有效降低造模剂引起的高尿酸血症,起到降尿酸作用;②肝脏组织XOD酶指标中,固体饮料组能有效抑制肝脏黄嘌呤氧化酶,从而降低血尿酸;③免疫荧光中发现固体饮料组能有效促进肾脏ABCG2蛋白表达,从而起到降低尿酸作用。
(3)固体饮料能有效改善痛风引起的肾脏损害,从而保护肾脏:①血液指标上发现固体饮料组能有效减轻血肌酐、尿素氮的表达水平,反应了固体饮料能有效降低尿酸保护肾脏;②肾脏HE中发现固体饮料组能有效改善肾小管萎缩及肾小管扩张,并减少肾间质炎症细胞浸润;③肾脏Masson染色中发现固体饮料组能有效减轻肾脏胶原纤维蛋白沉积,并且减轻肾小球基底膜增厚,改善了肾小球病变;肾脏PAS染色中发现固体饮料组能有效减少肾小球萎缩以及肾小球系膜的增厚,改善了肾小球的病变。
(4)药物安全上,固体饮料并未对肝肾脏器造成损害:①固体饮料组肝细胞均排列整齐,结构清晰,肝窦未见充血、淤血、坏死及炎症细胞浸润表现,肝索呈放射状排列;②固体饮料组未见肾脏小管及肾小球坏死等现象,而且能改善痛风疾病所带来的肾损害。
上述结果表明:固体饮料能起到降低尿酸、精准抗炎、靶向护肾作用,从而有效治疗痛风性关节炎。
综上所述,本发明实施例的固体饮料,几者配合能够有效抑制尿酸钠盐诱导的炎症反应,减少软骨的侵蚀及破坏;有效降低尿酸及保护肾脏,对肝肾器官无损害,安全性高;同时组方原料常见,易获得,价格低廉。其能够为治疗痛风性关节炎提供新的药物治疗方案。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (7)
1.一种固体饮料,其特征在于,按重量份数计,包括以下原料:薏苡仁150-200份,菊苣50-80份,茯苓50-80份,百合50-80份,葛根50-80份,桑叶20-40份,木瓜20-40份,金银花20-40份,绿茶5-20份和核桃肉5-20份。
2.根据权利要求1所述的固体饮料,其特征在于,按重量份数计,包括以下原料:薏苡仁180份,菊苣60份,茯苓60份,百合60份,葛根60份,桑叶30份,木瓜30份,金银花30份,绿茶10份和核桃肉10份。
3.一种如权利要求2所述的固体饮料的制备方法,其特征在于,包括以下步骤:
将原料粉碎,加水煎煮,过滤得到煎煮液,将煎煮液浓缩干燥,即得固体饮料。
4.根据权利要求3所述的固体饮料的制备方法,其特征在于,粉碎成100-200目的粉末,煎煮温度为70-100℃,煎煮时间为30-60min。
5.一种如权利要求1-4任一项所述的固体饮料在制备预防和/或治疗痛风性关节炎的药物中的应用。
6.根据权利要求5所述的固体饮料在制备预防和/或治疗痛风性关节炎的药物中的应用,其特征在于,所述药物还包括药学上可接受的载体或辅料。
7.根据权利要求6所述的固体饮料在制备预防和/或治疗痛风性关节炎的药物中的应用,其特征在于,所述药物为冲剂、散剂、片剂、丸剂、口服液、胶囊或软胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310401442.6A CN116421688A (zh) | 2023-04-15 | 2023-04-15 | 一种固体饮料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310401442.6A CN116421688A (zh) | 2023-04-15 | 2023-04-15 | 一种固体饮料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116421688A true CN116421688A (zh) | 2023-07-14 |
Family
ID=87082858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310401442.6A Withdrawn CN116421688A (zh) | 2023-04-15 | 2023-04-15 | 一种固体饮料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116421688A (zh) |
-
2023
- 2023-04-15 CN CN202310401442.6A patent/CN116421688A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN102512630B (zh) | 一种治疗胆囊结石的中药组合物 | |
CN106266463B (zh) | 一种用于治疗高尿酸血症的中药组合物及其应用 | |
AU2020103082A4 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation for treating gout and preparation method thereof | |
CN104524227A (zh) | 一种用于治疗龋齿的中药制剂及制备方法 | |
CN101987166A (zh) | 一种治疗麦粒肿的药物及其制备方法 | |
CN111920908A (zh) | 一种治疗消化性溃疡的药物组合物 | |
CN106310146A (zh) | 具有防治慢性肾衰功效的中药组合物及其制备方法与应用 | |
CN114404538B (zh) | 一种治疗痛风性关节炎的中药组合物及其应用 | |
CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN116421688A (zh) | 一种固体饮料及其制备方法和应用 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN108186945A (zh) | 一种用于治疗痛风的胶囊剂药物及其制备方法 | |
CN101327293B (zh) | 一种治疗消化性溃疡的胶囊及其制备方法 | |
CN112641889A (zh) | 理肠汤在制备治疗克罗恩病药物中的应用 | |
CN105327115A (zh) | 一种防治ⅱ型糖尿病桑黄通泻配方及制备工艺 | |
CN109125631A (zh) | 具有肝肾调节功能的中药组合物及其制备方法 | |
CN104147381B (zh) | 一种治疗高血压的中药组合物及其制备方法 | |
CN115814031B (zh) | 治疗痛风性关节炎的清热解毒组合物 | |
CN114767803B (zh) | 下调肾脏pdzk1蛋白防治高尿酸血症的铁皮石斛中药组合物及其制备方法和应用 | |
CN116650600B (zh) | 一种用于防治高尿酸血症及痛风的四药中药组合物、方法及应用 | |
CN116350728B (zh) | 一种降尿酸和/或抗炎止痛中药组合物及其应用 | |
CN108853380B (zh) | 治疗糖尿病的药物组合物及其制备方法和应用 | |
KR20080005592A (ko) | 급성 및 만성 기관지염의 치료용 약제의 제조에 있어서곤약 및 그 추출물의 용도 | |
CN106728718A (zh) | 一种治疗高尿酸血症的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230714 |